The continual spread of deadly pathogens coupled with the dwindling supply of antimicrobial treatments necessitates the development of effective prevention methods. However, the development of novel vaccines can be challenged by the incredible variability between microbial strains and the limitations associated with the vaccine manufacturing process.
At ATCC, we believe that it takes the combined efforts of dedicated scientists throughout the world to discover the treatments needed to keep humankind healthy and safe. That’s why we are committed to providing researchers with the virus-producing cell lines, pathogenic microbial strains, and purified pneumococcal polysaccharides needed to support vaccine research and development.
Together, we can work toward preventing and containing the world’s most devastating epidemics. Browse our resources below to discover how ATCC can support your vaccine research.
Watch our webinar about credible solutions for critical public health emergencies
Vaccine development tools
Cell lines for virus production
Antiviral vaccines are essential for preventing epidemic disease; however, the production of these therapeutics is often limited by low-yielding manufacturing processes. To address this, ATCC used cutting-edge CRISPR/Cas9 gene-editing technology to develop STAT1 knockout cell lines capable of producing high-titer viral stocks. These STAT1-KO cell lines are not only good candidates for enhancing virus titers for vaccine development, but also useful tools to package lentiviral, adenoviral, and retroviral vectors for the delivery of DNA sequences into target cells for various applications such as gene therapy and cancer immunotherapy.Discover More
Streptococcus pneumoniae is a major global health threat that is estimated to result in the death of one million children every year. While preventing the spread of this pathogenic bacterium through vaccination has been highly effective, the increasing rate of infections caused by non-vaccine serotypes presents new challenges toward containing the disease. To aid researchers in the analysis and prevention of pneumococcal disease, ATCC offers over 30 types of pneumococcal polysaccharides from various sources. These purified polysaccharides provide a unique tool for evaluating how effectively a vaccine can induce an immune response.Get More Info
The Need for Tuberculosis Reference Standards in Vaccine Development
Overall, there have been a number of factors attributed to the variations seen in BCG vaccine efficacy. Learn how manufacturers can come one step closer to improving BCG vaccine performance with a single consensus, biological standard that demonstrates high levels of protection when used in vaccine development.Download the Whitepaper